MedTrace Logo

CNI-1493 for Treatment of Moderate to Severe Crohn's Disease

NCT00038766 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2012-08-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether CNI-1493 is safe and effective in the treatment of moderate to severe Crohn's Disease.

Conditions

  • Crohn Disease

Interventions

DRUG

semapimod

semapipmod 60 mg IV x 5 days

DRUG

semapimod

IV 30 mg x 5 days

DRUG

placebo

placebo IV

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Daan Hommes, M · Academic Medical Center, Netherlands

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2003-06-30
Completion
2003-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00038766 on ClinicalTrials.gov